Bibliography
- De Grazia S, Carlomagno G, Unfer V, Cavalli P. Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects. Expert Opin Drug Deliv 2012;9:1033-9
- Orzalesi G, Gigli P, Canneri E. Dexamethasone-hydroxocobalamin combination in soft gelatine capsules. Boll Chim Farm 1968;107:822-7
- Babel W. Gelatine in pharmaceutical applications. Pharmaceut Manuf Packing Sourcer 2000;6:63-6
- Benvenga S, Bartolone L, Squadrito S, Delayed intestinal absorption of levothyroxine. Thyroid 1995;5:249-53
- Benvenga S, Bartolone L, Pappalardo MA, Altered intestinal absorption of coffee caused by coffee. Thyroid 2008;18:293-301
- Sindoni A, Vita R, Fusco S, Coffee impairs intestinal absorption of levothyroxine: report of additional cases. Hot Thyroidology 2009; no. 05/09. Available from: www.hotthyroidology.com/editorial_pdf/Sindoni_et_al_HT05_09.pdf)
- Colucci P, D’Angelo P, Mautone G, Pharmacokinetic equivalence of a levothyroxine soft capsule manufactured using the new Food and Drug Administration potency guidelines in healthy volunteers under fasting conditions. Ther Drug Monit 2011;33:355-61
- Benvenga S, Vita R, Saraceno G, Trimarchi F. A novel formulation of L-thyroxine (L-T4) solves problems of L-T4 malabsorption caused by coffee in patients under replacement or TSH-suppressive L-T4 therapy with conventional tablets (abstract 196). Program and Abstracts of the 81st Annual Meeting of the American Thyroid Association; 26 – 30 October; Indian Wells, CA. p. 233-4
- Benvenga S, Ducharme MP. Comparison of the intestinal absorption of levothyroxine (L-T4): tablet versus soft gel capsule formulation (abstract). 93rd Annual meeting of The Endocrine Society; 4 - 7 June 2011; Boston MA, USA
- Benvenga S, Ducharme MP. Effect of gastric pH on the bioavailability of levothyroxine (LT4) in soft gel capsules and in tablets: results from a pharmacokinetic study in healthy volunteers (abstract SUN-398). Program and Abstracts of the 94th Annual meeting of the Endocrine Society; 23 – 26 June 2012; Houston, TX, USA
- Vita R, Benvenga S. A case of L-T4 malabsorption caused by a proton pump inhibitor solved by a novel formulation of L-T4 (abstract MON-402). Program and Abstracts of the 94th Annual meeting of the Endocrine Society; 23 – 26 June 2012; Houston, TX, USA
- Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm 2009;72:105-10
- Saraceno G, Vita R, Trimarchi F, Benvenga S. A liquid formulation of L-thyroxine (L-T4) solves problems of incomplete normalization/suppression of serum TSH caused by proton pump inhibitors (PPI) on conventional tablet formulations of L-T4. 15th International & 14th European Congress of Endocrinology; 2012; In Endocrine Abstracts 29: P1626
- Carlomagno G, De Grazia S, Unfer V, Manna F. Myoinositol in a new h form: a step forward to a broader clinical use. Expert Opin Drug Deliv 2012;9:267-71